About Xelcis Bio™
Reinventing Cancer Therapy,
Starting with Chemotherapy
Xelcis Bio™ is a preclinical oncology company built on XELCIS XB, a platform designed to deliver cancer therapeutics into the cytosol of tumor cells, where they act. We are starting with chemotherapy. Our lead program, TDOX, is a targeted doxorubicin conjugate designed to overcome multidrug resistance and reduce cardiac exposure, followed by two dual-payload programs that pair doxorubicin with siRNA on the same particle
SCROLL
Who We Are
Focused on One of Oncology’s Most
Persistent Barriers
Xelcis Bio™ is a biotechnology company focused on solving one of the most persistent challenges in oncology drug development: achieving reliable cytosolic delivery. Many promising therapeutics fail not because the biology is wrong, but because the payload does not reach sufficient cytosolic concentrations to drive meaningful activity.
XELCIS XB is designed to overcome this limitation by moving therapeutic payloads beyond cellular uptake and into the cytosol, where intracellular targets can be engaged. We apply it first to our own programs, led by TDOX, and make the same platform available to partners whose assets face the same barrier.
Our Mission
Unlocking the Full Potential of Next-Generation Oncology Therapeutics
Our mission is to convert a demonstrated delivery advantage into better cancer therapeutics. By solving cytosolic delivery, we aim to develop our own oncology programs, starting with TDOX, and to expand the range of targets and modalities that become actionable across the field.
Platform Strategy
Programs Built on a Platform
XELCIS XB is a platform, and we are using it first to build our own therapeutics. The same delivery engine that powers TDOX and our combination programs also extends across modalities, from targeted chemotherapy and nucleic-acid therapeutics to nanobodies, biologics, and, longer term, targeted protein degradation. Every program we run makes the next one faster to develop and strengthens the platform we can offer partners.
Our Approach
Platform Strategy & Development Focus
Our development strategy advances our own programs into in vivo proof while generating data that also supports partner evaluation. The near-term focus is TDOX and the two combination programs, backed by the platform's cross-modality applicability.
Advancing Our Own Programs
TDOX leads toward IND-enabling work
Two dual-payload combination programs (siBIRC5 and siPD-L1 with doxorubicin) follow TDOX into in vivo studies after single-agent results
The platform extends across modalities from the same core chemistry
Reducing Development Risk
Improves probability of biological activity.
Strengthens translational confidence.
Supports more efficient development decisions.
Unlocks value across partner portfolios.
Built for Collaboration
We are engaging pharmaceutical and biotechnology companies to evaluate XELCIS XB as a delivery solution that can enhance programs, enable new targets, and reduce portfolio risk.
Our People
Experienced Leadership
Xelcis Bio™ is led by a team possessing extensive expertise in oncology drug development, delivery technologies, and organizational development; that is, a combination of scientific, clinical, and strategic competencies. The organization benefits from advisors and board members with significant experience in biotechnology, pharmaceutical development, and strategic partnerships.
Leadership Team
R. Michael Dudley
Co-Founder, CEO & Director
Qiyong Peter Liu, PhD
Co-Founder, Chief Science Officer
Rick Clemon, CPA, CGMA
Chief Financial Advisor
Candida Fratazzi, MD
Chief Medical Advisor
Subrata Ghosh, PhD
Director of Biology
Board of Directors
Alan Freidman
Co-Founder & Director, Business Advisor
_edited.png)
Ira S. Weinman, MBA
Independent Director
Cynthia Pussinen, MS
Independent Director
Rayna Lesser Hannaway, CFA
Independent Director
Advisors & Consultants
Dustan Bonnin, CVA, PAg, MBA
Co-Founder & Strategic Advisor
Sendurai Mani, PhD
Scientific Advisor
Suzanne Vyvoda
Clinical Operations Consultant
Looking Ahead
A Platform for the Next Generation of Oncology
By making cytosolic delivery more reliable and predictable, Xelcis aims to expand what is therapeutically achievable in oncology.
Enable Previously Inaccessible Targets
Targets limited by intracellular access may become actionable when cytosolic delivery is solved.
Improve Success Rates Across Modalities
Addressing delivery as a root cause of attrition may improve the probability of success across therapeutic classes.
Foundational Technology for Programs and Partners
XELCIS XB is built to power our own oncology pipeline and to serve as reliable cytosolic-delivery infrastructure for partner programs.